The ISIAT 2019 held in Lisbon in October was the occasion for LABRHA to present a study about HAppyMini® in the Hallux Rigidus (Osteoarthritis of the first metatarso-phalangeal joint).
This prospective open-label multicentre pilot trial was conducted on 65 patients and safety was very good : no severe or systemic adverse events were observed.
SEE THE COMPLETE PRESENTATION
LABRHA is supporting Eurovisco by organizing its annual board since 2014. We are proud to be Eurovisco’s partner. Viscosupplementation for the treatment of osteoarthritis. The contribution of EUROVISCO group Thierry Conrozier 1 , Raghu Raman Read more…
LABRHA is supporting Eurovisco by organizing its annual board since 2014. We are proud to be Eurovisco’s partner. Abstract Objectives: Hyaluronic acid viscosupplementation is a commonly used intra-articular treatment for osteoarthritis (OA). Some recent preclinical and Read more…
LABRHA is supporting Eurovisco by organizing its annual board since 2014. We are proud to be Eurovisco’s partner. Abstract Objectives The 3 aims of the work were to identify population subgroups that can benefit the Read more…